Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $9
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $10 to $9.
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $10 to $9.